Targeting gonadotropin-releasing hormone receptor inhibits the early step of ovarian cancer metastasis by modulating tumor-mesothelial adhesion

Molecular Therapy

Volumn 21, Issue 1, 2013, Pages 78-90

  Cheung, Lydia Wt ^a   Yung, Susan ^a   Chan, Tak Mao ^a   Leung, Peter Ck ^b   Wong, Alice St ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA3 INTEGRIN; ALPHA6 INTEGRIN; BETA3 INTEGRIN; CD51 ANTIGEN; COLLAGEN TYPE 1; FIBRONECTIN; GONADORELIN RECEPTOR; LAMININ; P CADHERIN; SCLEROPROTEIN; SMALL INTERFERING RNA; VERY LATE ACTIVATION ANTIGEN 2; VERY LATE ACTIVATION ANTIGEN 5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL ADHESION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESOTHELIUM CELL; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVARY CANCER; PERITONEUM METASTASIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84871923792     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.187     Document Type: Article

References (41)

1. Siegel, R, Naishadham, D and Jemal, A (2012). Cancer statistics, 2012. CA Cancer JClin 62: 10-29.
2. Naora, H and Montell, DJ (2005). Ovarian cancer metastasis: integrating insights fromdisparate model organisms. Nat Rev Cancer 5: 355-366. (Pubitemid 40637827)
3. Ayantunde, AA and Parsons, SL (2007). Pattern and prognostic factors in patients withmalignant ascites: a retrospective study. Ann Oncol 18: 945-949. (Pubitemid 47054094)
4. Hynes, RO (1992). Integrins: versatility, modulation, and signaling in cell adhesion.Cell 69: 11-25.
5. Gardner, MJ, Jones, LM, Catterall, JB and Turner, GA (1995). Expression of celladhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation toovarian cancer metastasis. Cancer Lett 91: 229-234.
6. Casey, RC and Skubitz, AP (2000). CD44 and beta1 integrins mediate ovariancarcinoma cell migration toward extracellular matrix proteins. Clin Exp Metastasis18: 67-75. (Pubitemid 32096052)
7. Elmasri, WM, Casagrande, G, Hoskins, E, Kimm, D and Kohn, EC (2009). Celladhesion in ovarian cancer. Cancer Treat Res 149: 297-318.
8. Schmidmaier, R and Baumann, P (2008). ANTI-ADHESION evolves to a promisingtherapeutic concept in oncology. Curr Med Chem 15: 978-990. (Pubitemid 351736400)
9. Emons, G, Pahwa, GS, Brack, C, Sturm, R, Oberheuser, F and Knuppen, R (1989).Gonadotropin releasing hormone binding sites in human epithelial ovariancarcinomata. Eur J Cancer Clin Oncol 25: 215-221. (Pubitemid 19054823)
10. Irmer, G, B?ger, C, M?ler, R, Ortmann, O, Peter, U, Kakar, SS et al. (1995).Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH)and its receptor in human ovarian epithelial carcinoma. Cancer Res 55: 817-822.
11. Cheung, LW, Leung, PC and Wong, AS (2006). Gonadotropin-releasing hormonepromotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinasemediatedactivation of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res66: 10902-10910. (Pubitemid 44876988)
12. Cheung, LW, Leung, PC and Wong, AS (2010). Cadherin switching and activation ofp120 catenin signaling are mediators of gonadotropin-releasing hormone to promotetumor cell migration and invasion in ovarian cancer. Oncogene 29: 2427-2440.
13. Cheung, LW, Mak, AS, Cheung, AN, Ngan, HY, Leung, PC and Wong, AS (2011).P-cadherin cooperates with insulin-like growth factor-1 receptor to promotemetastatic signaling of gonadotropin-releasing hormone in ovarian cancer via p120catenin. Oncogene 30: 2964-2974.
14. Weiss, JM, Diedrich, K and Ludwig, M (2002). Gonadotropin-releasing hormoneantagonists: pharmacology and clinical use in women. Treat Endocrinol 1: 281-291. (Pubitemid 37047235)
15. Buick, RN, Pullano, R and Trent, JM (1985). Comparative properties of five humanovarian adenocarcinoma cell lines. Cancer Res 45: 3668-3676. (Pubitemid 15226443)
16. Ahmed, N, Riley, C, Rice, G and Quinn, M (2005). Role of integrin receptors forfibronectin, collagen and laminin in the regulation of ovarian carcinoma functions inresponse to a matrix microenvironment. Clin Exp Metastasis 22: 391-402. (Pubitemid 41609298)
17. Tozer, EC, Hughes, PE and Loftus, JC (1996). Ligand binding and affinity modulationof integrins. Biochem Cell Biol 74: 785-798. (Pubitemid 126733740)
18. Chen, GT, Tai, CT, Yeh, LS, Yang, TC and Tsai, HD (2002). Identification of thecadherin subtypes present in the human peritoneum and endometriotic lesions:potential role for P-cadherin in the development of endometriosis. Mol Reprod Dev62: 289-294. (Pubitemid 34569109)
19. Shaw, TJ, Senterman, MK, Dawson, K, Crane, CA and Vanderhyden, BC (2004).Characterization of intraperitoneal, orthotopic, and metastatic xenograft models ofhuman ovarian cancer. Mol Ther 10: 1032-1042. (Pubitemid 39625247)
20. Harvey, W and Amlot, PL (1983). Collagen production by human mesothelial cellsin vitro. J Pathol 139: 337-347. (Pubitemid 13160679)
21. Stylianou, E, Jenner, LA, Davies, M, Coles, GA and Williams, JD (1990). Isolation,culture and characterization of human peritoneal mesothelial cells. Kidney Int 37:1563-1570. (Pubitemid 20198041)
22. Zhu, GG, Risteli, J, Puistola, U, Kauppila, A and Risteli, L (1993). Progressive ovariancarcinoma induces synthesis of type I and type III procollagens in the tumor tissue andperitoneal cavity. Cancer Res 53: 5028-5032. (Pubitemid 23326204)
23. Sneath, RJ and Mangham, DC (1998). The normal structure and function of CD44and its role in neoplasia. MP, Mol Pathol 51: 191-200. (Pubitemid 28394267)
24. Cannistra, SA, Kansas, GS, Niloff, J, DeFranzo, B, Kim, Y and Ottensmeier, C (1993).Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated byCD44H. Cancer Res 53: 3830-3838. (Pubitemid 23252051)
25. Strobel, T, Swanson, L and Cannistra, SA (1997). In vivo inhibition of CD44 limitsintra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novelrole for CD44 in the process of peritoneal implantation. Cancer Res 57: 1228-1232. (Pubitemid 27152541)
26. Lessan, K, Aguiar, DJ, Oegema, T, Siebenson, L and Skubitz, AP (1999). CD44 andbeta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells.Am J Pathol 154: 1525-1537. (Pubitemid 29226447)
27. Niedbala, MJ, Crickard, K and Bernacki, RJ (1985). Interactions of human ovariantumor cells with human mesothelial cells grown on extracellular matrix. Anin vitro model system for studying tumor cell adhesion and invasion. Exp Cell Res160: 499-513. (Pubitemid 16251304)
28. Wong, AS, Maines-Bandiera, SL, Rosen, B, Wheelock, MJ, Johnson, KR, Leung, PCet al. (1999). Constitutive and conditional cadherin expression in cultured humanovarian surface epithelium: influence of family history of ovarian cancer. Int J Cancer81: 180-188. (Pubitemid 29144744)
29. Patel, IS, Madan, P, Getsios, S, Bertrand, MA and MacCalman, CD (2003). Cadherinswitching in ovarian cancer progression. Int J Cancer 106: 172-177.
30. Takeichi, M (1995). Morphogenetic roles of classic cadherins. Curr Opin Cell Biol7: 619-627.
31. Gumbiner, BM (2005). Regulation of cadherin-mediated adhesion in morphogenesis.Nat Rev Mol Cell Biol 6: 622-634. (Pubitemid 41081266)
32. Sundfeldt, K (2003). Cell-cell adhesion in the normal ovary and ovarian tumors ofepithelial origin; an exception to the rule. Mol Cell Endocrinol 202: 89-96. (Pubitemid 36593398)
33. Buczek-Thomas, JA, Chen, N and Hasan, T (1998). Integrin-mediated adhesion andsignalling in ovarian cancer cells. Cell Signal 10: 55-63. (Pubitemid 28021336)
34. Cheung, LW, Ip, CK and Wong, AS (2010). Cadherin-catenin signaling in ovariancancer progression. In: Wu, WS and Hu, CT (eds). Signal Transduction in CancerMetastasis. Springer Life Sciences. pp. 225-253.
35. Comoglio, PM, Boccaccio, C and Trusolino, L (2003). Interactions between growthfactor receptors and adhesion molecules: breaking the rules. Curr Opin Cell Biol15: 565-571. (Pubitemid 37176965)
36. Geiger, B (1989). Cytoskeleton-associated cell contacts. Curr Opin Cell Biol 1: 103-109. (Pubitemid 19174524)
37. Verschraegen, CF, Westphalen, S, Hu, W, Loyer, E, Kudelka, A, Vker, P et al. (2003).Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist inpatients with platinum-resistant ovarian cancer. Gynecol Oncol 90: 552-559.
38. Emons, G, Grdker, C, Gthert, AR, Westphalen, S, Kavanagh, J and Verschraegen,C (2003). GnRH antagonists in the treatment of gynecological and breast cancers.Endocr Relat Cancer 10: 291-299. (Pubitemid 36758655)
39. Saleh-Abady, MM, Naderi-Manesh, H, Alizadeh, A, Shamsipour, F, Balalaie, S andArabanian, A (2010). Anticancer activity of a new gonadotropin releasing hormoneanalogue. Biopolymers 94: 292-297.
40. Kimball, KJ, Numnum, TM, Rocconi, RP and Alvarez, RD (2006). Gene therapy forovarian cancer. Curr Oncol Rep 8: 441-447.
41. Yung, S, Li, FK and Chan, TM (2006). Peritoneal mesothelial cell culture and biology.Perit Dial Int 26: 162-173. (Pubitemid 44336164)